These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37097304)

  • 41. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.
    Trisolini E; Armellini E; Paganotti A; Veggiani C; Bozzola C; Frattini M; Pizio C; Mancuso G; Andorno S; Boldorini R
    Pathology; 2017 Jun; 49(4):379-386. PubMed ID: 28450086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer.
    Sellahewa R; Moghaddam SM; Lundy J; Jenkins BJ; Croagh D
    Pancreas; 2023 Mar; 52(3):e188-e195. PubMed ID: 37751379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
    Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
    Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
    Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
    Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis.
    Ye P; Cai P; Xie J; Wei Y
    PLoS One; 2021; 16(3):e0248775. PubMed ID: 33770081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
    Luo Y; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
    Avsar T; Sursal A; Turan G; Yigit BN; Altunsu D; Cantasir K; Duyu G; Bayoumi AB; Yapicier O; Acar M; Kilic T
    Mol Diagn Ther; 2020 Jun; 24(3):327-338. PubMed ID: 32274701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.
    Buscail L; Bournet B; Cordelier P
    Nat Rev Gastroenterol Hepatol; 2020 Mar; 17(3):153-168. PubMed ID: 32005945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Transcriptome and
    Lundy J; Gao H; Berry W; Masoumi-Moghoddam S; Jenkins BJ; Croagh D
    Clin Cancer Res; 2021 Nov; 27(21):5900-5911. PubMed ID: 34400416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.
    Ako S; Kato H; Nouso K; Kinugasa H; Terasawa H; Matushita H; Takada S; Saragai Y; Mizukawa S; Muro S; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Nobuoka D; Yoshida R; Umeda Y; Yagi T; Okada H
    Cancer Biol Ther; 2021 Dec; 22(10-12):564-570. PubMed ID: 34632919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens.
    Sho S; Court CM; Kim S; Braxton DR; Hou S; Muthusamy VR; Watson RR; Sedarat A; Tseng HR; Tomlinson JS
    PLoS One; 2017; 12(1):e0170897. PubMed ID: 28125707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer.
    Suzuki T; Masugi Y; Inoue Y; Hamada T; Tanaka M; Takamatsu M; Arita J; Kato T; Kawaguchi Y; Kunita A; Nakai Y; Nakano Y; Ono Y; Sasahira N; Takeda T; Tateishi K; Uemura S; Koike K; Ushiku T; Takeuchi K; Sakamoto M; Hasegawa K; Kitago M; Takahashi Y; Fujishiro M;
    Cancer Sci; 2022 Sep; 113(9):3097-3109. PubMed ID: 35567350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration.
    Matsumoto K; Kato H; Nouso K; Ako S; Kinugasa H; Horiguchi S; Saragai Y; Takada S; Yabe S; Muro S; Uchida D; Tomoda T; Okada H
    Dig Dis Sci; 2020 Oct; 65(10):2907-2913. PubMed ID: 31897893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.